Semaglutide vs. Tirzepatide: How to Choose the Right GLP-1 Medication

If you have looked into medical weight loss in the past two years, you have run into two names: semaglutide (sold as Wegovy and Ozempic) and tirzepatide (sold as Zepbound and Mounjaro). Patients ask us almost every week which one is better. The honest answer is that both are effective, one has a modest edge on average, and the choice for any one person depends on more than the trial numbers. Here is how we think it through.

What they have in common

Both are once-weekly injections given under the skin. Both are FDA-approved for chronic weight management in adults with obesity (a BMI of 30 or higher) or overweight (a BMI of 27 or higher) with at least one weight-related condition, alongside a reduced-calorie diet and increased activity. Both began as type 2 diabetes medications (Ozempic and Mounjaro) before the weight-management versions (Wegovy and Zepbound) were approved.

They work the same basic way. They mimic gut hormones released after a meal, which slows stomach emptying, reduces appetite and "food noise," and helps you feel full sooner and for longer. Most people eat noticeably less without white-knuckling it, which is why these medications succeed where willpower alone tends to fail.

How they differ

Semaglutide (Wegovy, Ozempic)

Semaglutide activates one receptor, GLP-1. Wegovy was approved for weight management in June 2021 and, in its main trial (STEP 1), adults lost about 15% of their body weight over 68 weeks compared with about 2.4% on placebo. Since then its label has grown: in March 2024 it was approved to reduce the risk of heart attack, stroke, and cardiovascular death in adults with established cardiovascular disease and overweight or obesity; in August 2025 it received accelerated approval for MASH (fatty liver disease with scarring); a once-daily tablet form was approved in December 2025; and a higher-dose injection (Wegovy HD, 7.2 mg) was approved in March 2026.

Tirzepatide (Zepbound, Mounjaro)

Tirzepatide activates two receptors, GIP and GLP-1, which appears to add to its effect on appetite and metabolism. Zepbound was approved for weight management in November 2023. In its main trial (SURMOUNT-1), adults on the highest dose lost about 21% of their body weight over 72 weeks, roughly 18 percentage points more than placebo. In December 2024 it was also approved for moderate-to-severe obstructive sleep apnea in adults with obesity.

The head-to-head trial

Until 2025, comparisons relied on separate trials with different designs. SURMOUNT-5, published in the New England Journal of Medicine in July 2025, compared the two directly: 751 adults with obesity and no diabetes were randomized to the maximum tolerated dose of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) for 72 weeks.

• Average weight change: −20.2% with tirzepatide versus −13.7% with semaglutide (about 50 pounds versus 33 pounds for the average participant).
• Waist circumference: −18.4 cm with tirzepatide versus −13.0 cm with semaglutide.
• More people on tirzepatide reached the 10%, 15%, 20%, and 25% weight-loss thresholds.
• Stopping because of digestive side effects: 2.7% on tirzepatide versus 5.6% on semaglutide.

Two caveats matter. First, these are averages; plenty of people do very well on semaglutide, and some do not respond strongly to either. Second, the trial excluded people with diabetes and used the doses available in 2023–2024, before the higher-dose Wegovy HD existed. The gap may be narrower with today's options.

Side effects and safety: nearly identical

Because the two medications work through the same pathway, their side effects overlap almost completely.

• Digestive: nausea, vomiting, diarrhea, constipation, and reflux are the most common, usually during dose increases, and usually improve with time and a slower schedule.
• Less common but important: gallbladder problems, pancreatitis, and dehydration that can strain the kidneys. Tell us about any severe or persistent abdominal pain.
• Low blood sugar is uncommon unless you also take insulin or a sulfonylurea.
• Both carry a boxed warning about thyroid C-cell tumors seen in rodents; neither is used in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.
• Neither is used in pregnancy, and both should be stopped before trying to conceive; the timing differs by medication, so plan this with us.
• Tirzepatide can reduce the effectiveness of oral birth control for four weeks after starting and after each dose increase; a non-oral or barrier method is advised during those windows.
• Both slow stomach emptying, which matters before surgery or sedation. Tell your surgeon and anesthesiologist you are taking one.

Dosing and what the first months look like

Both medications start low and increase roughly every four weeks to limit side effects. Semaglutide moves from 0.25 mg to 0.5, 1, 1.7, and 2.4 mg weekly, so reaching the full dose takes about four to five months. Tirzepatide moves from 2.5 mg to 5, 7.5, 10, 12.5, and 15 mg weekly. Not everyone needs the top dose; we hold at the dose that is working and tolerated.

Expect a check-in with us monthly during the escalation phase, then every one to three months. Weight loss is usually steady rather than dramatic in the first month, and most of the effect arrives over the first six to twelve months.

How we choose at Reset You MD

We do not start anyone on a weight-loss medication at a first visit without an evaluation. The consultation is complimentary, and it is where we decide together whether medication belongs in your plan at all.

1. Your history and goals: how much weight, what you have tried, and what a realistic timeline looks like for your life.
2. Labs and body composition: metabolic labs (blood sugar, lipids, liver, kidney, thyroid) and a body-composition measurement so we can track fat and muscle, not just the scale.
3. Other conditions: established heart disease favors semaglutide's cardiovascular data; obstructive sleep apnea favors tirzepatide; fatty liver, PCOS, prediabetes, and medications you already take all shape the choice.
4. Tolerance: if you have struggled with nausea on semaglutide, tirzepatide's lower discontinuation rate is a reasonable reason to switch, and vice versa.
5. Cost and coverage: insurance rules, manufacturer savings programs, and whether a tablet (oral semaglutide) fits your preferences.

Whichever medication we choose, the plan is the same: protect muscle, adjust the dose to you, review labs, and plan for maintenance from the start. Weight regain after stopping is common with both medications, so we talk about the long term before the first injection.

The bottom line

On average, tirzepatide produces more weight loss than semaglutide, and fewer people stop it for digestive side effects. Semaglutide has the longer track record, cardiovascular-outcome data, and a tablet option. Both are good medications when they are prescribed for the right person and paired with nutrition, strength training, and follow-up. If you are weighing the two, bring your questions to a complimentary consultation and we will map out which one, if either, fits you.

Website content is for general education and does not replace individualized medical advice, diagnosis, or treatment. Individual results vary. This article is general education from a Florida physician and does not create a doctor–patient relationship; talk with your own clinician about your situation.